AlphaCrest Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

AlphaCrest Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-66,066	Closed	-$534K	–	1259
2022 Q2	$534K	Buy	66,066 +19,811	+43%	+$174K	0.03%	934
2022 Q1	$642K	Buy	+46,255	New	+$727K	0.04%	774
2021 Q4	–	Sell	-6,982	Closed	-$237K	–	1356
2021 Q3	$237K	Sell	6,982 -9,018	-56%	-$326K	0.01%	1176
2021 Q2	$654K	Buy	16,000 +4,300	+37%	+$167K	0.03%	850
2021 Q1	$471K	Buy	+11,700	New	+$633K	0.03%	824

Other funds holding ADPT

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BWLSA

Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AlphaCrest Capital Management's ADPT Position: Q3 2022 in Review

AlphaCrest Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q3 2022, closing a stake of 66,066 shares — an estimated $534K sold.

AlphaCrest Capital Management first reported a position in ADPT in Q1 2021 and held it in 5 quarters. The position peaked at $654K in Q2 2021. 226 funds tracked by Wall St. Rank hold ADPT as of Q3 2022.

AlphaCrest Capital Management reported no remaining Adaptive Biotechnologies position as of Q3 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 66,066 Adaptive Biotechnologies shares in Q3 2022, an estimated $534K.
AlphaCrest Capital Management first reported a position in Adaptive Biotechnologies in Q1 2021 and held it in 5 quarters.
AlphaCrest Capital Management's Adaptive Biotechnologies position peaked at $654K in Q2 2021.
226 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2022.

Based on AlphaCrest Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.